Stratrix
Company data sheet · Chemours

Chemours: left behind by its peers.

Industry
Chemicals & Allied Products Manufacturing
Headquarters
United States
Ticker
CC (NYSE)
Sources
SEC filings (2014–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
Data as of
October 18, 2026
  1. Left behind by its peers. From 2016 to 2025, its revenue grew 8% in US dollars; the median among 586 large manufacturers grew 58%. It outgrew only 17% of them.
  2. Still smaller than it was. Revenue reached $5.8 billion in 2025, 15% below its 2022 peak of $6.8 billion.
  3. Leaders came and went. Chemours filed 38 leadership changes since 2016, more than 92% of large manufacturers (the median is 19). The day after each, its shares rose a median 0.5 points against its sector.

Financial results

Fiscal yearRevenueNet income
2016$5.4 billion$0 billion
2017$6.2 billion$0.7 billion
2018$6.6 billion$1 billion
2019$5.5 billion−$0.1 billion
2020$5 billion$0.2 billion
2021$6.3 billion$0.6 billion
2022$6.8 billion$0.6 billion
2023$6.1 billion−$0.3 billion
2024$5.8 billion$0.1 billion
2025$5.8 billion−$0.4 billion

As reported in its annual filings. Losses in red.

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Market reaction to disclosed decisions: 66 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (43 with market data).
  • Economic context: 7 measures for the United States, every year since 2016, from the official sources.
  • Peer comparison: against 953 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.
Download the PDFDownload the ExcelSee the Data Plan

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.